LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
Status:
Recruiting
Trial end date:
2025-10-03
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, phase II, single-centre study, with one LXE408 regimen and
one calibrator arm with the standard of care SSG combined with PM, to be conducted in male
and female adult (≥18 years and <45 years) patients with confirmed primary visceral
leishmaniasis in Ethiopia.